Once again, Iβm incredibly grateful for the unwavering support of my advisor, @wchnicholas.bsky.social, and the invaluable contributions of all my co-authors. Thank you for helping bring this idea to life!
04.09.2025 02:07 β π 1 π 0 π¬ 0 π 0
GitHub - nicwulab/oPool_display: Antibody library selection
Antibody library selection. Contribute to nicwulab/oPool_display development by creating an account on GitHub.
With the help of Cursor Agent/Claude Sonnet 4, we created a locally run user interface for our design pipeline that enables quick and simple design of oligo pool-based native pairing antibody library assemblies. Have fun screening, it's a pool partyyy! :) github.com/nicwulab/oPo...
04.09.2025 02:07 β π 4 π 0 π¬ 1 π 0
I'm thrilled to share that the oPoolβΊ display is on the cover of this week's #ScienceTranslationalMedicine! We hope that the future use of this platform can accelerate antibody characterization, benefit therapeutic & vaccine development, and facilitate iterative refinements of antibody AI models.
04.09.2025 02:05 β π 14 π 5 π¬ 2 π 0
Reaching Out to Senior Scientists: A Step Worth Taking
When we start out as early career researchers, we often hesitate to reach out to senior scientists. However, they are often excited to help young scientists. Here, Owen Ouyang discusses how mentorship...
Academia is built on collaboration and mentorship. However, as ECRs, we tend to hesitate to reach out to our seniors. In our latest ecrLife post, @owenouyang.bsky.social encourages young scientists to give it a try, since many seniors are happy to write back and provide advice.
tinyurl.com/35u7hw5h
03.07.2025 16:59 β π 1 π 3 π¬ 0 π 0
9 Graduate Student "Rising Stars" smiling in a group photo at the end of a successful symposium
Had a blast listening to exciting science and stories at last week's 4th annual Graduate Student Rising Stars symposium @uofubiochem.bsky.social, topped off by a keynote describing the wonders of cone snail venoms from Toto Olivera. Thanks to all of our visitors and speakers!
28.05.2025 23:26 β π 6 π 3 π¬ 1 π 2
Iβm grateful for the unwavering support from my advisor @wchnicholas.bsky.social as well as everyone from the Wu Lab. It has been an amazing journey so far, and Iβm excited for more to come! We envision a near future where antibody binding characterization is fast, simple, and cost-effective. (14/)
03.03.2025 14:35 β π 1 π 0 π¬ 0 π 0
oPool+ display also holds promise for advancing toward the future synergy between machine learning models and experimental systems by enabling rapid validation of prediction results at scale. We believe it represents a starting point for the future of high-throughput antibody biology. (13/)
03.03.2025 14:33 β π 1 π 0 π¬ 1 π 0
oPool+ display can be generalized to any antigens of interest as long as they can be recombinantly purified. More importantly, oPool+ display also offers great flexibility in experimental design, as the synthesized library can be stored, reused, and expanded at any time. (12/)
03.03.2025 14:32 β π 1 π 0 π¬ 1 π 0
This result suggests that a diverse native pairing library of ~20,000 unique antibody sequences can be assembled in just one 96-well plate PCR reaction, followed by concurrent specificity characterization against 10-20 antigens of choice within days. Such a scale would be truly unprecedented. (11/)
03.03.2025 14:31 β π 1 π 0 π¬ 1 π 0
In the update, we tested the limit of our assembly strategy as we increased the # of scFv to assemble in a single PCR. Our one-pot PCR strategy performed amazingly well, as it achieved extremely high reproducibility and coverage even with the assembly of different 200 scFvs in a single tube. (9/)
03.03.2025 14:30 β π 1 π 0 π¬ 1 π 0
Through computational design, we overcame this challenge by splitting a defined scFv sequence into fragments and assembling them back through PCR. To ensure precise assembly, we utilized the highly diverse CDR regions to computationally design overlaps that are unique at the nucleotide level. (9/)
03.03.2025 14:21 β π 1 π 0 π¬ 1 π 0
The key innovation of oPool+ display lies within the assembly of native paring antibodies, as current technologies does not permit massively parallel oligo synthesis >350nt, which is only 1/3 of the length of a single-chain variable fragment (scFv), the shortest human antibody format. (8/)
03.03.2025 14:20 β π 1 π 0 π¬ 1 π 0
We then selected 25 antibodies and thoroughly tested their binding against all 9 HAs by both BLI (using Fab) and ELISA (using IgG). Both validations indicated >70% of true positive rate and >95% of true negative rate, demonstrating the robust performance of oPool+ display. (7/)
03.03.2025 14:19 β π 1 π 0 π¬ 1 π 0
Our screening showed that 114 of the 325 antibodies bound to at least one of the nine HA screened, 45 of which were further identified to target the more conserved stem domain through either HA stem screens or binding competition with CR9114, a known HA stem antibody. (6/n)
03.03.2025 14:17 β π 1 π 0 π¬ 1 π 0
As a proof-of-concept, we applied oPool+ display to rapidly synthesize >300 uncharacterized and uncommon influenza hemagglutinin (HA) antibodies and measure their binding to 9 HA variants through 16 different screens. Over 5,000 binding tests were performed in < 5 days. (5/)
03.03.2025 14:13 β π 1 π 0 π¬ 1 π 0
To address this, we combined oligo pool synthesis with mRNA display to synthesize and screen antibodies with defined sequences at scale. Compared to the conventional approaches, our platform is significantly faster (~3-5 days), costs ~80-90% less, and only requires one person to perform it. (4/)
03.03.2025 14:09 β π 1 π 0 π¬ 1 π 0
Considering that hundreds to thousands of natively paired antibody sequences can usually be isolated in a clinical study, this process would often take dedicated research teams weeks to months to complete and cost up to hundreds of thousands of dollars. A bottleneck clearly exists. (3/)
03.03.2025 14:07 β π 1 π 0 π¬ 1 π 0
Antibody discovery is crucial to developing therapeutics and understanding adaptive immunity. However, despite years of research, the characterization of monoclonal antibodies today remains low throughput, as it involves cloning, expressing, and characterizing each antibody one by one (2/)
03.03.2025 14:06 β π 1 π 0 π¬ 1 π 0
world map with pins showing the locations of E life ambassadors
1/ From Brazil to South Korea, weβre excited to welcome 107 early-career researchers who are looking to promote responsible behaviours in science to the eLife Community Ambassador programme π
https://buff.ly/3EYNfmE
27.02.2025 15:03 β π 10 π 5 π¬ 1 π 6
OK, #immunology Bluesky LFG!
If, like me, you're trying to reconstruct the vibrant scientific network we had at the other place, these starter packs are a great start:
go.bsky.app/2bqX3T7
go.bsky.app/PY5tCas
go.bsky.app/FmERUoD
go.bsky.app/AjNpW2h
go.bsky.app/SinqoJU
go.bsky.app/DmphBCT
18.11.2024 19:06 β π 61 π 22 π¬ 6 π 1
Official BlueSky account for the Lab of Pamela Bjorkman at the California Institute of Technology. Structural Biology π¬ Immunologyπ₯ΌVirology π¦ Vaccine π www.its.caltech.edu/~bjorker
Ph.D candidate in Roh-Johnson Lab at Utah Biochem studying Dictyostelium cell-substrate adhesions and cell migration | Evolutionary Cell Bio aficionado | Harvard β17 | π²π½ | @ascbiology.bsky.social COMPASS Co-Chair | Cientifico Latino
π phdβing in bioinformatics & computational biology @ unc chapel hill | phanstiel lab | interests: genome org & function 𧬠| hhmi gilliam '24 | nsf grfp β22 | π
occidental college β21 |πhost, from where does it stem? | ποΈ co-founder @sciforgood.bsky.social
Postdoc in the @rutterlab.bsky.social. Interests: cell signaling and metabolism.
protein biochemistry and evolution | viruses and antibodies | faculty @uofubiochem.bsky.social
starr.biochem.utah.edu
PhD @UofIllinois; Bio-Painter; Programmer; Active learner #Influenza #Bioinformatics #Deep_learning Website:http://yiquan2.com
Stanford BioE, Genetics & Sarafan ChEM-H. Chan-Zuckerberg Biohub Investigator. Our lab develops and applies microfluidic assays for high-throughput biophysics and biochemistry.
Director of Virology at HDT Bio. Developing RNA platform for emerging infectious diseases. πΏπ¦π°π·
Lab studying molecular evolution of proteins and viruses. Affiliated with Fred Hutch & HHMI.
https://jbloomlab.org/
Infectious diseases & genomics. Immunologist in (voluntary) exile. Minimal sarcasm. Fierce HOA (Hater of Acronyms). Personal account - opinions expressed are my own and not those of my employer.
Virologist. PI at VIDO, University of Saskatchewan. Co-EiC of Vaccine. πΊπΈ in π¨π¦. Emerging viruses, pathogenesis, zoonosis, host responses, dogs, football, off-color language, transcriptomic chaos. Opinions my own.
Virologist β£ | Trying to understand why viruses tick the way they do - then, now and in future | π©πͺπͺπΊπΊπ³
@themeyerlab.bsky.social
Virus spotter. You're twistin' my melon man.
[He, him.] CMV virologist exploring how viruses
enter cells and other tricky mischief (lately, of the glycoimmune-centric variety). University of Pittsburgh School of Medicine. My posts here are my own speech, not my employerβs. #LoveVirology #Glycotime
A coronavirus lab looking for low hanging pebbles and shiny fruit.
Emory University
Mosquitoes, watches and whatever. Huck Chair of Disease Epidemiology and Biotechnology at Penn State. My opinions do not reflect those of my employer (they want nothing to do with them whatsoever)
rasgonlab.wordpress.com
Virologist. Likes history, hiking, tea, coffee & a good movie.Favourite viruses? Coronavirus, Emerging & Oncogenic Viruses. Favourite country? UK. Dad. Bibliophile.
Virologist at the University of Queensland. #virology #virusevolution #rnavirology
#NewPI in #RNA #Virology, electron microscopy aficionado, gardener, parent, Assistant Professor
@UVMLarnerMed. Prev @Gates_Cambridge scholar
Semi-retired biotechnologist and virologist, interested in making vaccines, lover of 70s rock and hard SF. And good red wine. Posts are both personal and professional, and may include music and/or strong opinions. And possibly zombies.